Introduction
============

Human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer constitutes \~20% of breast cancer cases ([@b1-mmr-14-06-5104]). Overexpression of the HER2 protein is caused by amplification of the HER2 gene. HER2-overexpressing cancer often has a highly aggressive phenotype and is associated with metastasis to the lymph nodes and distant organs; among breast cancer types the prognosis for this type of cancer is the worst ([@b2-mmr-14-06-5104]--[@b4-mmr-14-06-5104]). Using anti-HER2 antibodies as molecular target-based therapy may ameliorate the prognosis of HER2-overexpressing breast cancer ([@b5-mmr-14-06-5104]). However, the molecular mechanism underlying the aggressive behavior of HER2-overexpressing breast cancer remains to be fully elucidated.

Delta-HER2 is a splice variant of HER2, which lacks the 16 amino acids (coded by 48 nucleotides) of exon 16 in the extracellular domain ([Fig. 1](#f1-mmr-14-06-5104){ref-type="fig"}) ([@b6-mmr-14-06-5104],[@b7-mmr-14-06-5104]). The deletion of these 16 amino acids in the cysteine-rich region generates unpaired cysteine residues, which cause chemical dimerization of the molecules and constitutive stimulation of cell proliferation ([@b8-mmr-14-06-5104],[@b9-mmr-14-06-5104]). It has been reported *in vitro* that overexpression of delta-HER2 in cultured cells results in the generation of highly proliferative cells ([@b8-mmr-14-06-5104]--[@b12-mmr-14-06-5104]). Furthermore, in transgenic mice overexpressing delta-HER2, mammary carcinoma frequently developed, whereas overexpression of wild type (wt)-HER2 did not induce tumor formation ([@b13-mmr-14-06-5104]). The findings of these *in vitro* experiments and animal models indicated that delta-HER2 is oncogenic.

The expression levels of delta-HER2 have been examined in cell lines and in human breast cancer tissues ([@b8-mmr-14-06-5104],[@b9-mmr-14-06-5104],[@b11-mmr-14-06-5104],[@b12-mmr-14-06-5104],[@b14-mmr-14-06-5104]); however, in some studies the number of patients is limited and the expression was examined by semi-quantitative methods ([@b9-mmr-14-06-5104],[@b14-mmr-14-06-5104]). The expression of delta-HER2 and its association with the clinicopathological factors of human breast cancer remain to be fully elucidated. Furthermore, to the best of our knowledge, the expression levels of delta-HER2 in Japanese patients with HER2-overexpressing breast cancer remain unknown.

The present study established a quantitative method to detect delta-HER2 mRNA expression in formalin-fixed paraffin-embedded cancer specimens. The aim of the present study was to explore the expression of delta-HER2 and its clinicopathological correlation in Japanese cases of HER2-overexpressing breast cancer.

Patients and methods
====================

### HER2-overexpressing breast cancer and histological evaluation

A total of 40 cases of breast cancer, which were given a score of 3 by HER2 immunostaining, were retrieved from the archival files. The present study was performed using formalin-fixed paraffin-embedded specimens of primary breast cancer in all cases except case \#8. In this case, the specimen was obtained from the metastatic lymph nodes, and information regarding the primary tumor was not obtained. The present study was approved by the Ethical Committee of Hirosaki University (Hirosaki, Japan). The histology of the breast cancers was classified according to the World Health Organization Classification of Breast Tumors ([@b15-mmr-14-06-5104]). The HER2 immunostaining score was determined according to the guidelines recommended by American Society of Clinical Oncology/College of American Pathologists ([@b16-mmr-14-06-5104]). No patients received preoperative neoadjuvant therapy.

### Total RNA extraction and synthesis of cDNA

Total RNA was extracted from the paraffin-embedded sections using RNeasy FFPE kit (Qiagen K.K., Tokyo, Japan). Briefly, five slices from the 4 µM-thick paraffin-embedded sections were deparaffinized using xylene and ethanol, and dried. Subsequently, the sections were digested with proteinase K solution until the tissues were completely dissolved. Total RNA was purified using spin columns, according to the manufacturer\'s protocol. As a standardization control, cDNA reverse-transcribed from a mixture of total RNA extracted from the normal breast tissues of five women (age, 34, 45, 47, 59 and 78 years) (BioChain Institute Inc., Newark, CA, USA) was used. cDNA was synthesized from 2 µg total RNA by reverse transcription using the SuperScript III First Strand cDNA Synthesis system (Thermo Fisher Scientific, K.K., Tokyo, Japan). The cDNA synthesis was primed by random hexamers.

### Quantitative polymerase chain reaction (qPCR) of wt-HER2 and delta-HER2

The delta-HER2 lacks exon 16, from which 16 amino acids are coded. Exon 16 is positioned at the extracellular domain close to the transmembrane region. The PCR primers used in the present study were designed to specifically amplify each transcript of wt-HER2 and delta-HER2. The primer sequences were as follows: wt-HER2, forward 5′-TCCTGTGTGGACCTGGATGA-3′; delta-HER2, forward 5′-GCACCCACTCCCCTCTGA-3′; and common reverse primer, 5′-CGCTTGATGAGGATCCCAAA-3′ (FASMAC Co. Ltd., Kanagawa, Japan) ([Fig. 1](#f1-mmr-14-06-5104){ref-type="fig"}). qPCR was conducted using SsoFast™ EvaGreen^®^ Supermix with Low ROX (Bio-Rad Laboratories, Inc., Tokyo, Japan). A 20 µl reaction solution contained 300 nM forward and reverse primers and cDNA transcribed from 40 ng total RNA as a template. The reaction program was initiated by denaturation at 96°C for 5 min, followed by 40 cycles at 96°C for 5 sec and 67°C for 30 sec. The quantification of 18S rRNA was conducted using TaqMan Master Mix and 18S rRNA Primer and Probe kit (Thermo Fisher Scientific, K.K.) with cDNA transcribed from 40 ng total RNA. The reaction program was initiated by 50°C for 2 min and 95°C for 10 min, followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. The changes in fluorescence were monitored using the ABI Prism 7000 Sequence Detection system (Thermo Fisher Scientific, K.K.).

Quantification cycle (Cq) of wt-HER2 (Cq~wt-HER2~), delta-HER2 (Cq~delta-HER2~) and 18S rRNA (Cq~18S\ rRNA~) was determined as the cycle where the linear increase in fluorescence reached the threshold level. Firstly, wt-HER2 and delta-HER2 were standardized by 18S rRNA, and ΔCq was calculated as ΔCq~wt-HER2~ = Cq~wt-HER2~ - Cq~18S\ rRNA~ and ΔCq~delta-HER2~ = Cq~delta-HER2~ - Cq~18S\ rRNA~, respectively. The relative expression levels were then calculated using the 2^−ΔΔCq^ formula ([@b17-mmr-14-06-5104]), where ΔΔCq was calculated by subtracting ΔCq of normal breast tissues from ΔCq of breast cancer tissues. The mRNA expression levels of wt-HER2 and delta-HER2 in breast cancer tissues were calculated as a fold increase or decrease relative to normal breast tissues.

The specificity of PCR was determined by the amplification of wt-HER2 and delta-HER2 from the mixture of wt-HER2 and delta-HER2 templates. The templates were mixtures of purified PCR products of wt-HER2 and delta-HER2 at concentration ratios of 100:0.1, 10:1, 1:10, 0.1:100 fg/tube, respectively. PCR was conducted by the same method used for qPCR. After the reaction, the PCR products were electrophoresed on 3% agarose gel.

### Immunostaining and scoring

Paraffin-embedded sections (4 µm) were immunostained with antibodies against estrogen receptor (ER; clone SP1; cat. no. 790-4324; 100 µl of prediluted antibody; Roche Diagnostics K.K., Tokyo, Japan), progesterone receptor (PgR; clone 1E2; cat. no. 790-2223; 100 µl of prediluted antibody; Roche Diagnostics K.K.), Ki-67 (clone MIB-1; cat. no. M7240; 1:100 dilution; DAKO Japan, Tokyo, Japan) and activated form of phosphorylated SRC (pSRC; Tyr416; cat. no. 2101; 1:100 dilution; Cell Signaling Technology Japan, K.K., Tokyo, Japan). Immunostaining was conducted using the Ventana BenchMark GX (Roche Diagnostics K.K.) automated staining system, and the peroxidase reaction was visualized by diaminobenzidine.

Nuclear staining was considered positive for ER, PgR and Ki-67. The expression of ER and PgR was scored according to the method reported by Allred *et al* ([@b18-mmr-14-06-5104]), and a total score ≥3 was considered positive. The Ki-67 index was calculated as a ratio (%) of the number of positive nuclei per 1,000 neoplastic cells in the area of the highest labeling, which is also known as the 'hot spot.' Cytoplasmic staining close to the cell membrane was considered positive for pSRC, and the expression was scored semiquantitatively as follows. When there was no staining, the tumor was scored as 0. If the cells were stained, the staining was scored between 1 and 3. A score of 1 was defined as weak staining, the same as some normal epithelial cells; a score of 3 was defined as strong membranous and cytoplasmic staining. A score of 2 indicated staining intensity between scores 1 and 3.

### Hierarchical clustering and statistical analysis

Hierarchical clustering and statistical analysis were performed using JMP 10 (SAS Institute Japan, Tokyo, Japan). The comparison between two groups was conducted using Mann-Whitney U test, and the comparison among three groups was performed using the Steel-Dwass method. The regressions between wt-HER2 and delta-HER2 mRNA levels and between wt-HER2 mRNA level and delta/wt ratio was examined by regression analysis. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinicopathological features of HER2-overexpressing breast cancer

A total of 40 cases of HER2-overexpressing breast cancer were studied in the present study, all of which were women, aged between 35 and 85 years ([Table I](#tI-mmr-14-06-5104){ref-type="table"}). Breast cancer histology ([Fig. 2](#f2-mmr-14-06-5104){ref-type="fig"}) observed sheet-like, cribriform and trabecular proliferation of atypical cells, which possessed irregular-shaped nuclei with prominent nucleoli and frequent mitotic figures ([Fig. 2A](#f2-mmr-14-06-5104){ref-type="fig"}). All cases were diagnosed as invasive carcinoma and histological grades were high. Strong expression of HER2 was identified on the cell membrane ([Fig. 2B](#f2-mmr-14-06-5104){ref-type="fig"}). A total of 20 cases were classified as hormone receptor-positive luminal B subtype ([Fig. 2C](#f2-mmr-14-06-5104){ref-type="fig"}), and the other 20 cases were classified as hormone receptor-negative HER2-positive subtype. The Ki-67 index ranged between 19.0 and 92.3% ([Fig. 2D](#f2-mmr-14-06-5104){ref-type="fig"}). A total of 23 cases had lymph node metastasis at the time of operation, and recurrence was noted in 10 cases.

### mRNA expression levels of wt-HER2 and delta-HER2

The specificity of qPCR was confirmed by amplifying a mixture of sequentially diluted wt-HER2 and delta-HER2 mRNA ([Fig. 3A](#f3-mmr-14-06-5104){ref-type="fig"}). The amount of each amplified product correlated with the amount of target in the mixture, and no cross-reaction was detected.

The expression levels of wt-HER2 and delta-HER2 varied largely, from 0.5 to 598.4-fold and from 0.3 to 499.7-fold compared with normal breast tissues, respectively ([Table I](#tI-mmr-14-06-5104){ref-type="table"}). There was a power regression between wt-HER2 and delta-HER2 mRNA levels (r^2^=0.86, P\<0.0001; [Fig. 3B](#f3-mmr-14-06-5104){ref-type="fig"}). The delta/wt ratio ranged between 0.1 and 6.2% ([Fig. 3C](#f3-mmr-14-06-5104){ref-type="fig"}); the average was 2.2±1.0%. There was a weak inverse correlation between delta/wt ratio and the mRNA expression levels of wt-HER2 (r^2^=0.1, [Fig. 3C](#f3-mmr-14-06-5104){ref-type="fig"}).

### Immunostaining of pSRC

Immunostaining of the activated form of pSRC was negative in six cases (15%). Weak and moderate positive immunostaining, scored as 1 and 2, was detected in 10 and nine cases, respectively (25 and 23%) ([Fig. 2E](#f2-mmr-14-06-5104){ref-type="fig"}). Strong immunostaining of pSRC, scored as 3, was noted in 15 cases (38%; [Fig. 2F](#f2-mmr-14-06-5104){ref-type="fig"}). The strong positive reaction was detected on the cell membrane and in the cytoplasm close to the cell membrane.

### Hierarchical clustering and clinicopathological features

Hierarchical clustering with wt-HER2, delta-HER2 and pSRC separated the HER2-overexpressing breast cancer cases into three major clusters ([Fig. 4A](#f4-mmr-14-06-5104){ref-type="fig"}). In cluster 1, the expression levels of wt-HER2 and delta-HER2 were lower than those in the other clusters ([Fig. 4B and C](#f4-mmr-14-06-5104){ref-type="fig"}). The mRNA expression levels of wt-HER2 and delta-HER2 were elevated in clusters 2 and 3, and the pSRC score was high in the majority of cases in these clusters ([Fig. 4A-C](#f4-mmr-14-06-5104){ref-type="fig"}). Delta/wt ratio appeared to be slightly higher in cluster 1 compared with those in the other clusters; however, the difference did not reach statistical significance ([Fig. 4D](#f4-mmr-14-06-5104){ref-type="fig"}). The Ki-67 index was high in all clusters; however, a trend was observed that the index was lower in cluster 1 compared with in clusters 2 and 3 ([Fig. 4E](#f4-mmr-14-06-5104){ref-type="fig"}).

The clinicopathological characteristics of cases in the three clusters were analyzed ([Table II](#tII-mmr-14-06-5104){ref-type="table"}). There was no difference in the intrinsic subtypes and primary tumor staging among the clusters. Lymph node status and recurrence were more frequent in cluster 1; however, the differences did not reach statistical significance ([Table II](#tII-mmr-14-06-5104){ref-type="table"}).

### Association between delta/wt ratio and clinicopathological features

Associations between the delta/wt ratio and clinicopathological features, such as intrinsic subtypes, lymph node status and disease recurrence were further analyzed. There was no significant difference in delta/wt ratio between HER2-positive and luminal B cases ([Fig. 5A](#f5-mmr-14-06-5104){ref-type="fig"}). However, the delta/wt ratio was significantly elevated in lymph node-positive cases ([Fig. 5B](#f5-mmr-14-06-5104){ref-type="fig"}) and in cases with recurrence ([Fig. 5C](#f5-mmr-14-06-5104){ref-type="fig"}). No significant differences in wt-HER2 and delta-HER2 mRNA levels were detected between intrinsic subtypes, lymph node status and recurrence (data not shown).

Discussion
==========

The present study detected delta-HER2 mRNA expression, a splice variant of HER2, in Japanese patients with HER2-overexpressing breast cancer. The mRNA expression levels of delta-HER2 mRNA appeared to be correlated with those of wt-HER2 mRNA. The HER2-overexpressing breast cancer were separated into cancer with elevated delta-HER2 and enhanced pSRC, and cancer with low expression level of delta-HER2, but with elevated delta/wt ratio. Furthermore, the delta/wt ratio was significantly increased in breast cancer cases with lymph node metastasis and recurrence.

In the present study, the breast cancer cases were separated into three clusters by hierarchical clustering with wt-HER2, delta-HER2 and pSRC. Tumors with moderate and high mRNA expression levels of wt-HER2 and delta-HER2 (clusters 2 and 3; [Fig. 4A](#f4-mmr-14-06-5104){ref-type="fig"}) presented enhanced phosphorylation of SRC and an increased Ki-67 index. These results are consistent with the findings of a previous report, which indicated that overexpression of delta-HER2 induces phosphorylation of SRC and stimulates the proliferative activity of breast cancer cells ([@b9-mmr-14-06-5104]). It is also plausible that the expression of other HER family molecules, such as epidermal growth factor receptor and HER3, may affect the phosphorylation of SRC; however, the expression of these molecules was not examined in the present study ([@b11-mmr-14-06-5104],[@b19-mmr-14-06-5104]). It is conceivable that HER2-overexpressing breast cancer cases are heterogeneous in the expression of wt-HER2 and delta-HER2, and intracellular signaling.

In 19 out of 40 cases (48%), delta- and wt-HER2 expression was relatively low, and SRC was only moderately phosphorylated or remained unphosphorylated (cluster 1; [Fig. 4A](#f4-mmr-14-06-5104){ref-type="fig"}). In addition, in cluster 1 the Ki-67 index appeared slightly lower compared with in the other clusters ([Fig. 4D](#f4-mmr-14-06-5104){ref-type="fig"}). However, there was a trend that lymph node metastasis was more frequent in these patients compared with the patients from the other clusters ([Table II](#tII-mmr-14-06-5104){ref-type="table"}). This finding appears to be in contrast with that of a previous report, which demonstrated that high frequency of lymph node metastasis was present in cases with high expression levels of delta-HER2 ([@b9-mmr-14-06-5104]). Furthermore, cases with a 'high delta-HER2 signature', which was identified in a cell line with delta-HER2 overexpression, had a worse prognosis in distant metastasis-free survival ([@b12-mmr-14-06-5104]). In the current study, the follow-up duration may be too short to determine effects on worse prognostic factors, such as local recurrence and distant metastasis. In addition, the number of patients in the present study was limited. There may also be ethnic differences in the biological behavior of HER2-overexpressing breast cancer ([@b20-mmr-14-06-5104]).

The delta/wt ratio in cluster 1 exhibited a trend to be higher than in the other clusters. Therefore, the association between clinicopathological characteristics and the delta/wt ratio was further examined. The delta/wt ratio was significantly higher in cases with lymph node metastasis and recurrence compared with in the cases without them. The mRNA expression levels of delta-HER2 and wt-HER2 were comparable in the two groups. Delta/wt ratio may be a good biological marker for the prediction of aggressive behavior of HER2-overexpressing breast cancer in Japanese patients. It may be valuable to use formalin-fixed paraffin-embedded specimens for the quantification of wt-HER2 and delta-HER2 mRNA expression.

The efficacy of trastuzumab on delta-HER2-overexpressing breast cancer is controversial. Delta-HER2 may chemically dimerize through disulfide bond formation and stimulate the signaling pathway to promote proliferation of tumor cells ([@b8-mmr-14-06-5104],[@b11-mmr-14-06-5104],[@b13-mmr-14-06-5104]). In a previous study, proliferation was not inhibited by trastuzumab in tumor cells overexpressing delta-HER2 *in vitro* ([@b8-mmr-14-06-5104],[@b9-mmr-14-06-5104]). Conversely, *in vivo*, the growth of implanted tumor cells in nude mice was inhibited by trastuzumab ([@b12-mmr-14-06-5104],[@b14-mmr-14-06-5104]). Furthermore, human patients with high levels of delta-HER2 and enhanced pSRC followed a better clinical course, as compared with the cases with low levels of delta-HER2 and pSRC, following treatment with trastuzumab ([@b14-mmr-14-06-5104]). The discrepancy of the efficacy of trastuzumab between *in vitro* and *in vivo* conditions may, in part, be due to the presence of immunological machinery against HER2-overexpressing tumor cells *in vivo* ([@b21-mmr-14-06-5104]). Further examination is required to elucidate the effects of trastuzumab on Japanese patients with HER2-overexpressing breast cancer.

In conclusion, the current study demonstrated the expression of delta-HER2 in HER2-overexpressing breast cancer from Japanese patients. The enhanced expression of delta-HER2 was associated with phosphorylation of SRC, whereas the increase in the delta/wt ratio was associated with lymph node metastasis and recurrence. The delta/wt ratio may be a valuable biomarker to predict the prognosis of HER2-overexpressing breast cancer. Further examination is required to elucidate the precise molecular effects induced by delta-HER2.

The authors of the present study would like to thank Dr Shunji Aizawa and Dr Akimasa Nishimura for their assistance and invaluable suggestions.

![Structure of wt-HER2 and delta-HER2, and PCR primers for mRNA expression analysis.](MMR-14-06-5104-g00){#f1-mmr-14-06-5104}

![Histological features of HER2-positive breast cancer. (A) Sheet-like proliferation of carcinoma cells, which possessed irregular-shaped nuclei with prominent nucleoli (×40 magnification). (B) Strong continuous expression of HER2 was observed on the cell membrane (×200 magnification). (C) Positive reaction of estrogen receptor in tumor cells (×200 magnification). (D) Representative immunostaining of Ki-67 in tumor tissue (×200 magnification). Representative immunostaining of phosphorylated-SRC of (E) score 1 and (F) score 3 (×400 magnification). HER2, human epidermal growth factor receptor 2.](MMR-14-06-5104-g01){#f2-mmr-14-06-5104}

![Molecular features and mRNA expression levels of wt-HER2 and delta-HER2. (A) Electrophoresis of PCR products amplified from a mixture of wt-HER2 and delta-HER2 templates. (B) Correlation between wt-HER2 and delta-HER2 mRNA expression levels. (C) Correlation between wt-HER2 and delta/wt ratio. The ratio tends to be slightly high in the cases with low mRNA expression levels of delta-HER2. HER2, human epidermal growth factor receptor 2; PCR, polymerase chain reaction; wt, wild type.](MMR-14-06-5104-g02){#f3-mmr-14-06-5104}

![Hierarchical clustering of wt-HER2, delta-HER2 and pSRC, and association with clinicopathological factors. (A) Unsupervised hierarchical clustering of wt-HER2 and delta-HER2 and pSRC separated the breast cancer cases into three major clusters. The levels of (B) wt-HER2 mRNA and (C) delta-HER2 mRNA were significantly higher in clusters 2 and 3 (\*P\<0.05 vs. cluster 1, \*\*P\<0.05 vs. cluster 2). (D) The delta/wt ratio tended to be higher and (E) Ki-67 index tended to be lower in cluster 1, compared with in clusters 2 and 3. HER2, human epidermal growth factor receptor 2; pSRC, phosphorylated-SRC; wt, wild type.](MMR-14-06-5104-g03){#f4-mmr-14-06-5104}

![Association between the delta/wt human epidermal growth factor receptor 2 ratio and clinicopathological features. (A) Delta/wt ratio was comparable between intrinsic subtypes. Delta/wt ratio was significantly higher in (B) LN-positive cases (\*P\<0.05 vs. LN-negative cases) and in (C) cases with recurrence (\*P\<0.05 vs. cases without recurrence). LN, lymph node.](MMR-14-06-5104-g04){#f5-mmr-14-06-5104}

###### 

Clinicopathological features of patients with HER2-overexpressing breast cancer.

  No.   Age (yr)   Intrinsic subtype   pT   Ki-67(%)   LN   Metastasis       wt-HER2 (fold)   delta-HER2 (fold)   delta/wt(%)   pSRC
  ----- ---------- ------------------- ---- ---------- ---- ---------------- ---------------- ------------------- ------------- ------
    1   35         LumB                2    49.6       −                     46.2             32.3                1.5           2
    2   38         LumB                3    19.0       \+   Br               54.8             49.5                3.9           1
    3   42         HER2^+^             2    82.0       \+   Ms               16.6             25.7                3.4           1
    4   42         LumB                1    16.7       −    Br, Li           4.0              3.1                 1.7           1
    5   42         LumB                2    38.5       \+   Br               1.1              1.1                 2.1           0
    6   42         LumB                1    69.3       \+                    23.3             46.4                3.4           0
    7   43         HER2^+^             1    52.7       \+                    3.6              5.4                 3.4           2
    8   43         HER2^+^             −    87.5       \+   Li, Lg, Bn, LN   41.5             50.9                2.1           3
    9   43         LumB                1    42.1       −                     10.2             8.7                 1.9           3
  10    45         HER2^+^             1    44.3       \+   Br               7.5              21.0                6.2           1
  11    46         LumB                2    55.5       \+   Br, Skin         5.7              7.2                 2.8           0
  12    47         LumB                1    29.4       \+                    0.5              0.3                 1.4           1
  13    48         HER2^+^             1    44.9       −    Br               6.6              8.1                 2.7           1
  14    48         LumB                1    79.4       −                     94.4             222.1               3.0           2
  15    49         LumB                2    44.5       −    Br, Bn           598.4            19.3                0.1           2
  16    50         LumB                2    75.2       −                     169.5            150.1               2.0           3
  17    50         LumB                4    43.7       \+                    25.4             15.7                1.5           2
  18    50         LumB                2    69.4       −                     39.7             40.4                1.8           3
  19    51         HER2^+^             2    74.8       \+                    113.4            83.6                1.3           3
  20    52         LumB                1    58.4       −                     4.1              4.0                 2.2           3
  21    53         HER2^+^             1    78.2       −                     24.9             20.6                1.9           3
  22    55         HER2^+^             2    63.4       −                     177.3            156.0               1.5           0
  23    56         HER2^+^             4    69.7       \+                    432              499.7               2.6           2
  24    57         HER2^+^             2    92.3       \+                    87.7             114.2               2.3           2
  25    57         LumB                1    67.3       −                     0.8              0.6                 1.6           2
  26    59         HER2^+^             1    64.7       \+                    9.3              7.8                 1.9           2
  27    60         HER2^+^             1    68.5       −                     70.0             56.1                1.4           3
  28    61         HER2^+^             1    51.2       −                     2.0              1.8                 2.1           1
  29    64         HER2^+^             2    68.2       \+                    6.7              3.8                 1.3           1
  30    64         HER2^+^             1    43.7       \+                    1.7              2.4                 3.2           0
  31    64         HER2^+^             1    31.8       −                     100.8            177.3               3.0           1
  32    65         LumB                1    56.4       −                     315.2            128.9               0.7           3
  33    68         HER2^+^             1    88.0       \+                    15.1             20.2                2.3           1
  34    69         HER2^+^             4    92.3       \+   LN               30.6             32.9                2.4           3
  35    72         HER2^+^             2    72.0       −                     4.1              3.9                 1.7           0
  36    73         LumB                1    28.5       \+                    10.9             9.8                 2.0           3
  37    73         LumB                1    52.7       −                     11.8             6.7                 1.0           3
  38    78         LumB                2    74.4       \+                    55.7             64.9                2.0           3
  39    81         HER2^+^             2    34.6       \+                    3.9              3.6                 2.1           3
  40    85         LumB                2    80.1       −                     203.7            370.9               2.4           3

Bn, bone; Br, brain; HER2^+^, human epidermal growth factor receptor 2-positive; LumB, luminal B; Lg, lung; Li, liver; LN, lymph node; Ms, muscle; pSRC, phosphorylated-SRC; pT, primary tumor staging; wt, wild type; yr, years of the age.

###### 

Comparison of clinicopathological features among the human epidermal growth factor receptor 2-overexpressing breast cancer clusters.

                      Clusters            
  ------------------- ---------- ---- --- ---------
  Intrinsic subtype                       P=0.92
    Luminal B         9          6    5   
    HER2-positive     10         6    4   
  pT                                      P=0.753
    1                 11         6    3   
    2                 6          4    5   
    3                 1          0    0   
    4                 1          1    1   
  Lymph node status                       P=0.065
    −                 6          6    7   
    +                 13         6    2   
  Recurrence                              P=0.236
    −                 12         10   8   
    +                 7          2    1   

pT, primary tumor staging.
